CCO INTELLIGENCE

The Patent Cliff Countdown

The clock is ticking. Billions in revenue will vanish the moment your patents expire.

Patent Cliff Countdown

Revenue at risk from upcoming patent expirations

$12.4B
Revenue at Risk
NEXT PATENT EXPIRY: Cardiomax
89
DAYS
0
HOURS
0
MINS
Current Annual Revenue
$4.2B
→
Post-Expiry (Est.)
$0.6B
7 generic competitors filed
Portfolio Patent Timeline
89d
Cardiomax
$4.2B annual revenue
-85% expected
-$3.6B
NowPatent Expiry
234d
Neurozen
$2.8B annual revenue
-78% expected
-$2.2B
NowPatent Expiry
456d
Immunoforce
$6.1B annual revenue
-72% expected
-$4.4B
NowPatent Expiry
612d
Oncoguard
$3.5B annual revenue
-65% expected
-$2.3B
NowPatent Expiry
Total Portfolio
$16.6B
At Risk (2yr)
$12.4B
Generic Filings
19
Urgency Level
CRITICAL
1 Critical (<100d)
1 Warning (<300d)
2 Safe (>300d)
Revenue at Risk Formula: $4.2B × 85% + $2.8B × 78% + $6.1B × 72% + $3.5B × 65% = $12.4B at risk(that is 75% of your $16.6B portfolio)

The Cliff Edge Approaches

Protection Expires

Years of R&D investment protected by a single date. When the patent expires, 7+ generic competitors are waiting to capture 80% of your volume within months.

Revenue Freefall

A $4B blockbuster becomes a $400M commodity overnight. Your entire commercial infrastructure built around that product becomes stranded cost.

Time Runs Out

Every day of inaction is lost revenue. Without a replacement product or mitigation strategy, you're watching billions evaporate with a countdown timer.

The Cliff in Numbers

$170B
at risk through 2030
85%
avg revenue erosion post-LOE
12 mo
to full generic penetration
7+
avg generic entrants per product

Navigate the Cliff Edge

SlideStrike transforms patent portfolio data into strategic countdown dashboards that drive proactive cliff mitigation.

Portfolio Countdown

Mitigation Planning

Patent Cliff FAQ

QHow much revenue is typically lost when a patent expires?

Branded drugs typically lose 70-90% of revenue within 12-18 months of generic entry. The first generic usually captures 40-50% market share within 6 months.

QWhat is the $170B patent cliff?

Between 2025-2030, over $170B in branded drug sales face patent expiration. This is the largest patent cliff in pharma history, affecting blockbusters in oncology, immunology, and cardiology.

QCan anything slow generic erosion?

Strategies include: authorized generics, lifecycle management, switching patients to next-gen products, and maximizing brand loyalty pre-expiry. Each buys time but rarely prevents eventual erosion.

QHow early should patent cliff planning begin?

Best practice is 5-7 years before expiry. This allows time to develop lifecycle extensions, launch next-gen products, and build alternative revenue streams.

Face the Cliff. Plan the Descent.

See how SlideStrike helps CCOs visualize patent risk and build proactive mitigation strategies.

Request Patent Cliff Demo